SCAI and HRS Release Expert Consensus on Transcatheter Left Atrial Appendage Closure

WASHINGTON — The Society for Cardiovascular Angiography & Interventions (SCAI) and the Heart Rhythm Society (HRS) released an updated expert consensus statement on transcatheter left atrial appendage closure (LAAC). SCAI and HRS prioritized the development of an updated consensus statement to provide recommendations on contemporary, evidence-based best practices for transcatheter LAAC focusing on endovascular devices.

Left atrial appendage closure is a minimally invasive procedure that is used to reduce the risk of stroke associated with atrial fibrillation. Atrial fibrillation is a common form of arrhythmia, a condition in which the heart beats out of rhythm. Atrial fibrillation (AF) is associated with a 4- to 5-fold increased risk of ischemic stroke and accounts for 25% of the 700,000 cerebrovascular accidents that occur in the United States annually.

Summary of Recommendations:

1. Transcatheter LAAC is appropriate for patients with nonvalvular atrial fibrillation with high thromboembolic risk who are not suited for long-term oral anticoagulation and who have adequate life expectancy.

2.1. Physicians performing LAAC should have prior experience, including ≥50 prior left-sided ablations or structural procedures and ≥25 transseptal punctures (TSPs). Interventional imaging physicians should have experience in guiding ≥25 TSPs before supporting any LAAC procedures independently.

2.2. For maintenance of skills, implanting physicians should perform ≥25 TSPs and >12 LAACs over each 2-year period.

2.3. New programs and implanting physicians early in their LAAC experience should have on-site cardiovascular surgery backup.

3. Baseline imaging with transesophageal echocardiography (TEE) or cardiac computed tomography is recommended before LAAC.

4. Intraprocedural imaging guidance with TEE or intracardiac echocardiography is recommended.

5. Technical aspects of the procedure, including venous access, anticoagulation, transseptal puncture, delivery sheath selection and placement, left atrial pressure measurement, and device deployment, should be performed in accordance with the labeling of each specific LAAC device.

6. Operators need to be familiar with avoidance, recognition, and management of procedural complications associated with LAAC.

7. Predischarge imaging should be performed with 2-dimensional transthoracic echocardiography to rule out pericardial effusion and device embolization.

8. Device-related thrombus should be treated with anticoagulation.

9. Routine closure of iatrogenic atrial septal defects associated with LAAC should not be performed.

10. The clinical impact and management of peridevice leaks are not fully understood, and all efforts should be made to minimize such leaks at the time of implantation.

11. Patients should be prescribed antithrombotic therapy with warfarin, direct oral anticoagulants, or dual antiplatelet therapy after LAAC according to the studied regimen and instructions for use for each specific device and tailored to the bleeding risks of each patient.

12. TEE or cardiac computed tomography is recommended at 45 to 90 days after LAAC for device surveillance to assess for peridevice leak and device-related thrombus.

13. Combined procedures with LAAC (e.g., structural interventions, pulmonary vein isolation) are not routinely recommended, as data are pending from ongoing randomized controlled trials.

“This consensus statement demonstrates the evolvement of LAAC treatment since our first statements that were issued in 2015 and 2016,” stated Jacqueline Saw, MD, FSCAI, chair of the writing group and an interventional cardiologist at Vancouver General Hospital and St Paul’s Hospital, Clinical Professor of Medicine at UBC, and Program Director of the VGH Interventional Cardiology Fellowship Program. “Since then, the results from several important clinical trials and registries, as well as other technological and clinical advancements have evolved and changed the way we look at operator requirements, patient selection, and shared decision making, which explains the need for this updated guidance.”

This statement has been developed according to the SCAI Publications Committee policies for writing group composition, disclosure, and management of relationships with industry, internal and external review, and organizational approval. The writing group has been organized to ensure diversity of perspectives and demographic characteristics, multistakeholder representation, and appropriate balance of relationships with industry. Relevant financial disclosures are available in the manuscript.

The American College for Cardiology and the Society of Cardiovascular Computed Tomography endorsed the statement.

About the Society for Cardiovascular Angiography & Interventions

The Society for Cardiovascular Angiography & Interventions (SCAI) is a nonprofit professional association with over 4,500 members representing interventional cardiologists and cardiac catheterization teams in the United States. SCAI promotes excellence in interventional cardiovascular medicine for both adults and children through education, representation, and the advancement of quality standards to enhance patient care. Follow @SCAI on Twitter for the latest heart health news.

About the Heart Rhythm Society

The Heart Rhythm Society (HRS) is a 501(c)(3) international nonprofit organization and the preeminent leader in science, education, and advocacy for cardiac arrhythmia professionals and patients. HRS continues to be the primary information resource on heart rhythm disorders with a mission to improve the care of patients by promoting research, education, and optimal health care policies and standards, and a mission to eliminate death and suffering due to heart rhythm disorders. Incorporated in 1979 and based in Washington, D.C., it has a membership of more than 7,500 heart rhythm professionals in more than 90 countries around the world. For more information, visit www.HRSonline.org.